CABLEarnings•globenewswire•
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (35)
Summary
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire